Bruna Giribaldi

Bruna Giribaldi, BSc, is a clinical researcher who has collaborated closely with leading teams in contemporary psychedelic science, notably at Imperial College London's Centre for Psychedelic Research. She is a co‑author on high‑profile clinical trials — including the multicentre Trial of Psilocybin versus Escitalopram for Depression — and on work examining neurobiological and clinical changes following psilocybin therapy. Her roles have spanned participant assessment, trial conduct and contributing to neuroimaging and outcome analyses.

Giribaldi's published contributions cover both quantitative clinical outcomes and mixed‑methods investigations: neuroimaging studies reporting increased global brain integration after psilocybin therapy, trials comparing psilocybin with standard antidepressant treatment (including personality and six‑month follow‑up assessments), and focused analyses on moderators of response (for example body mass index, therapeutic alliance and the role of music). She has also been involved in research exploring broader functional domains such as sexual functioning after psychedelic use and in methodological guidance for conducting rigorous psychedelic clinical research. Her work emphasises integration of clinical, neurobiological and process‑level measures to understand therapeutic mechanisms and optimise clinical protocols.